SPLICE to CURE
Transforming Immunotherapy Through Splicing Modulation
IMMUNOA is pioneering new molecular tools to improve immunotherapy
IMMUNOA Pte. Ltd. is a biotech startup that aims to create tools that improve existing and investigational immunotherapies for cancer treatment.
We are an A*STAR (Agency for Science, Technology And Research) technology spin-off founded in 2018 with R&D based in Singapore.
Small molecules, antibodies or CRISPR-based approaches can be used to inhibit or reduce the amount of target proteins.
What we are trying to do at IMMUNOA is different.
We are harnessing alternative splicing to develop tools to switch from a "bad" isoform to a "good" isoform.
By doing so we obtain a dual therapeutic effect that can significantly advance immunotherapy treatments in solid tumors.
Get in touch
Institute of Molecular and Cell Biology (IMCB)
Proteos, 61 Biopolis Drive,
GMP cell facility & Office
(co-locate with Lion TCR)
JTC Medtech Hub
2 Tukang Innovation Grove, #09-04
Tel: +65 6926 0818